Ajanta Pharma Reports Strong Q1 FY2027 Results; Revenue Up 25%, PAT Jumps 31%

Ajanta Pharma Reports Strong Q1 FY2027 Results; Revenue Up 25%, PAT Jumps 31%​

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, announced excellent performance for the first quarter of the financial year 2027 (Q1 FY 2027) ended June 30, 2026. The company reported substantial growth across its operations, highlighted by robust revenue and profit increases compared to the corresponding period in FY 2026.

The Board of Directors approved an interim dividend of Rs. 32 per share for shareholders. This dividend, based on the face value of Rs. 2 per share, is valued at Rs. 400 cr. The record date set for the payment of this interim dividend is Wednesday, August 5, 2026, with disbursement scheduled on or after August 18, 2026.

Q1 FY2027 Financial Highlights​

The consolidated results reflect a strong market response to Ajanta Pharma’s portfolio. The company reported the following key financial metrics for Q1 FY 2027 against Q1 FY 2026:


The company also recorded a healthy Return on Capital Employed (ROCE) at 37% and Return on Net Worth (RONW) at 28%.

Segment-wise Operational Performance​

Ajanta Pharma maintains a diversified business structure, spanning multiple regions. The segment performance, consolidated across all markets, showed significant growth:

Branded Generic Insights and R&D Focus​

The company’s India branded generic segment performed particularly well. As per IQVIA data for March (MAT) June 2026, the performance of India branded generics exceeded IPM growth by 36%. This outperformance was attributed to new launches that exceeded Indian Pharmaceutical Market (IPM) growth by 76%, and volume growth exceeding IPM by 40%.

In terms of global market penetration, Ajanta Pharma has a significant focus on chronic therapies across multiple regions. The company’s R&D expenditure reflected this strategic focus in the first quarter. For Q1 FY 2027, the R&D expense stood at ₹ 66 cr, compared to ₹ 56 cr for FY 2026.

Ajanta Pharma is a specialty pharmaceutical formulation company with a major focus on branded generic business across India, Asia, and Africa. The company has operational presence in 34+ countries globally and maintains a state-of-the-art R&D center in Mumbai.

AJANTPHARM Stock Price Movement​

As of 2:41 PM, Ajanta Pharma Limited shares edge higher in live trading, gaining 1.17% and reaching ₹3436.1. The stock maintained steady momentum throughout the session, having seen 66,442 shares traded so far today.